A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
- Status
- SUSPENDED
- Phase
- PHASE2
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
- Status
- UNKNOWN
- Phase
- N/A
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
- Status
- UNKNOWN
- Phase
- N/A
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- Status
- RECRUITING
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
- Status
- RECRUITING
- Phase
- PHASE2
Tucatinib Together With Pembrolizumab and Trastuzumab
- Status
- TERMINATED
- Phase
- PHASE2
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3